Technical Analysis for CMPX - Compass Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 1.70 | 3.66% | 0.06 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | 3.66% | |
| MACD Bearish Centerline Cross | Bearish | 3.66% | |
| Oversold Stochastic | Weakness | 3.66% | |
| 20 DMA Resistance | Bearish | -0.58% | |
| Oversold Stochastic | Weakness | -0.58% | |
| 50 DMA Support | Bullish | 0.00% | |
| Bullish Engulfing | Bullish | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| 50 DMA Resistance | about 22 hours ago |
| 10 DMA Resistance | about 23 hours ago |
| 2x Volume Pace | about 23 hours ago |
| 1.5x Volume Pace | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/06/2024
Compass Therapeutics, Inc. Description
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Its scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Immune System Antibodies Oncology Tumor Human Diseases Immune Checkpoint Tumor Microenvironment Angiogenesis Oncology Focused Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.34 |
| 52 Week Low | 0.765 |
| Average Volume | 460,775 |
| 200-Day Moving Average | 1.51 |
| 50-Day Moving Average | 1.69 |
| 20-Day Moving Average | 1.80 |
| 10-Day Moving Average | 1.74 |
| Average True Range | 0.13 |
| RSI (14) | 46.52 |
| ADX | 20.17 |
| +DI | 20.22 |
| -DI | 20.42 |
| Chandelier Exit (Long, 3 ATRs) | 1.69 |
| Chandelier Exit (Short, 3 ATRs) | 1.97 |
| Upper Bollinger Bands | 2.03 |
| Lower Bollinger Band | 1.57 |
| Percent B (%b) | 0.28 |
| BandWidth | 25.51 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0332 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.85 | ||||
| Resistance 3 (R3) | 1.85 | 1.81 | 1.83 | ||
| Resistance 2 (R2) | 1.81 | 1.77 | 1.81 | 1.82 | |
| Resistance 1 (R1) | 1.75 | 1.74 | 1.78 | 1.75 | 1.81 |
| Pivot Point | 1.71 | 1.71 | 1.72 | 1.71 | 1.71 |
| Support 1 (S1) | 1.65 | 1.67 | 1.68 | 1.65 | 1.59 |
| Support 2 (S2) | 1.61 | 1.64 | 1.61 | 1.58 | |
| Support 3 (S3) | 1.55 | 1.61 | 1.58 | ||
| Support 4 (S4) | 1.55 |
